Overview

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Status:
Completed
Trial end date:
2018-10-25
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Blocking
Antibodies, Monoclonal